BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.

AI/ML

Biotechnology

Pharmaceutical

Therapeutics

BigHat Bio

Mark DePristo

Randy Schreckhise

Vi Vu

Abiy Seifu

John Corbin

Mitchell Stieg

Leslie Grab

Danielle Landrein

Timothy Park

Charbel Eid

Eddie Abrams

Liz Schwarzbach

Peyton Greenside

The Software Development Team at BigHat Bio leverages advanced programming and machine learning techniques to develop and maintain the AI-enabled experimental platform that accelerates antibody engineering. This team collaborates to create robust software solutions, integrate machine learning models, and automate experimental processes, thereby enhancing the platform's efficiency and precision in designing next-generation antibody therapeutics.

Software Development Team

Research Team

Advisory Team

Software Development Team

About

Team members

Other teams at BigHat Bio

Research Team

Advisory Team